Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Am J Hum Genet. 2024 Oct 3;111(10):2150-2163. doi: 10.1016/j.ajhg.2024.08.009. Epub 2024 Sep 12.
The tumor immune microenvironment (TIME) plays key roles in tumor progression and response to immunotherapy. Previous studies have identified individual germline variants associated with differences in TIME. Here, we hypothesize that common variants associated with breast cancer risk or cancer-related traits, represented by polygenic risk scores (PRSs), may jointly influence immune features in TIME. We derived 154 immune traits from bulk gene expression profiles of 764 breast tumors and 598 adjacent normal tissue samples from 825 individuals with breast cancer in the Nurses' Health Study (NHS) and NHSII. Immunohistochemical staining of four immune cell markers were available for a subset of 205 individuals. Germline PRSs were calculated for 16 different traits including breast cancer, autoimmune diseases, type 2 diabetes, ages at menarche and menopause, body mass index (BMI), BMI-adjusted waist-to-hip ratio, alcohol intake, and tobacco smoking. Overall, we identified 44 associations between germline PRSs and immune traits at false discovery rate q < 0.25, including 3 associations with q < 0.05. We observed consistent inverse associations of inflammatory bowel disease (IBD) and Crohn disease (CD) PRSs with interferon signaling and STAT1 scores in breast tumor and adjacent normal tissue; these associations were replicated in a Norwegian cohort. Inverse associations were also consistently observed for IBD PRS and B cell abundance in normal tissue. We also observed positive associations between CD PRS and endothelial cell abundance in tumor. Our findings suggest that the genetic mechanisms that influence immune-related diseases are also associated with TIME in breast cancer.
肿瘤免疫微环境(TIME)在肿瘤进展和免疫治疗反应中起着关键作用。先前的研究已经确定了与 TIME 中个体种系变异相关的个体种系变异。在这里,我们假设与乳腺癌风险或癌症相关特征相关的常见变体(由多基因风险评分(PRS)表示)可能共同影响 TIME 中的免疫特征。我们从 825 名乳腺癌患者的 764 个肿瘤和 598 个相邻正常组织样本的批量基因表达谱中得出了 154 个免疫特征。对于 205 名个体的亚组,可进行四种免疫细胞标志物的免疫组织化学染色。针对 16 种不同的特征(包括乳腺癌、自身免疫性疾病、2 型糖尿病、初潮和绝经年龄、体重指数(BMI)、BMI 调整后的腰臀比、酒精摄入量和吸烟)计算了种系 PRS。总体而言,我们在错误发现率 q<0.25 下确定了种系 PRS 与免疫特征之间的 44 种关联,其中包括 3 种与 q<0.05 的关联。我们观察到炎症性肠病(IBD)和克罗恩病(CD)PRS 与干扰素信号和 STAT1 评分在乳腺癌肿瘤和相邻正常组织中呈负相关;这些关联在挪威队列中得到了复制。在正常组织中,IBD PRS 与 B 细胞丰度之间也观察到了负相关。我们还观察到 CD PRS 与肿瘤中内皮细胞丰度之间的正相关。我们的研究结果表明,影响免疫相关疾病的遗传机制也与乳腺癌的 TIME 相关。